Expression-Based Subtypes Define Pathologic Response to Neoadjuvant Immune-Checkpoint Inhibitors in Muscle-Invasive Bladder Cancer
Checkpoint immunotherapy (CPI) has increased survival for some patients with advanced stage bladder cancer (BCa). However, most patients do not respond. Here, we characterized the tumor and immune microenvironment in pre- and post-treatment tumors from the PURE01 neoadjuvant pembrolizumab immunotherapy trial, using a consolidative approach that combined transcriptional and genetic profiling with digital spatial profiling.
- Type: Other
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Dataset ID | Description | Technology | Samples |
---|---|---|---|
EGAD00001007998 | Illumina HiSeq 4000 | 4 | |
EGAD00001007999 | Illumina NovaSeq 6000 | 6 | |
EGAD00001008000 | Illumina NovaSeq 6000 | 6 | |
EGAD00001008001 | Illumina HiSeq 2500 | 12 | |
EGAD00001008002 | Illumina HiSeq 2500 | 31 | |
EGAD00001008003 | Illumina HiSeq 4000 | 82 |
Publications | Citations |
---|---|
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer.
Nat Commun 14: 2023 2126 |
20 |